BG107064A - Фармацевтични форmи - Google Patents

Фармацевтични форmи Download PDF

Info

Publication number: BG107064A
Authority: BG; Bulgaria
Prior art keywords: pharmaceutical formulations; formulations according; sucrose; release; fatty acid
Prior art date: 2000-03-08

Application number

BG107064A

Other languages

Bulgarian (bg)

English (en)

Inventor

Torsten Hoffmann

Michael Pieroth

Gerhard Zessin

Karl-Friedrich Landgraf

Original Assignee

Awd.Pharma Gmbh & Co.Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-08

Filing date

2002-09-05

Publication date

2003-04-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26004678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG107064(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-03-08 Priority claimed from DE2000110509 external-priority patent/DE10010509A1/de

2002-09-05 Application filed by Awd.Pharma Gmbh & Co.Kg filed Critical Awd.Pharma Gmbh & Co.Kg

2003-04-30 Publication of BG107064A publication Critical patent/BG107064A/bg

Links

-1 sucrose fatty acid esters Chemical class 0.000 claims abstract description 57
239000000194 fatty acid Substances 0.000 claims abstract description 56
235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 54
229930195729 fatty acid Natural products 0.000 claims abstract description 54
229930006000 Sucrose Natural products 0.000 claims abstract description 47
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 47
239000005720 sucrose Substances 0.000 claims abstract description 47
238000000034 method Methods 0.000 claims abstract description 42
239000000203 mixture Substances 0.000 claims abstract description 35
238000005469 granulation Methods 0.000 claims abstract description 31
230000003179 granulation Effects 0.000 claims abstract description 31
239000003795 chemical substances by application Substances 0.000 claims abstract description 10
239000003814 drug Substances 0.000 claims abstract description 9
238000004519 manufacturing process Methods 0.000 claims abstract description 5
239000008203 oral pharmaceutical composition Substances 0.000 claims abstract description 5
238000005453 pelletization Methods 0.000 claims abstract description 5
239000013543 active substance Substances 0.000 claims description 95
239000008187 granular material Substances 0.000 claims description 41
238000002844 melting Methods 0.000 claims description 36
230000008018 melting Effects 0.000 claims description 34
239000003826 tablet Substances 0.000 claims description 32
PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 claims description 31
229960003312 retigabine Drugs 0.000 claims description 31
239000000546 pharmaceutical excipient Substances 0.000 claims description 23
239000001959 sucrose esters of fatty acids Substances 0.000 claims description 21
235000010965 sucrose esters of fatty acids Nutrition 0.000 claims description 21
230000008569 process Effects 0.000 claims description 19
239000008188 pellet Substances 0.000 claims description 17
150000004665 fatty acids Chemical class 0.000 claims description 16
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 15
229960000623 carbamazepine Drugs 0.000 claims description 15
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 14
229940095670 calcium valproate Drugs 0.000 claims description 13
238000002360 preparation method Methods 0.000 claims description 13
239000011230 binding agent Substances 0.000 claims description 12
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 12
229960001597 nifedipine Drugs 0.000 claims description 12
238000000576 coating method Methods 0.000 claims description 9
239000002552 dosage form Substances 0.000 claims description 9
150000002148 esters Chemical class 0.000 claims description 9
238000003756 stirring Methods 0.000 claims description 8
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 7
239000011248 coating agent Substances 0.000 claims description 7
229940079593 drug Drugs 0.000 claims description 7
239000001069 triethyl citrate Substances 0.000 claims description 7
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 7
235000013769 triethyl citrate Nutrition 0.000 claims description 7
238000007757 hot melt coating Methods 0.000 claims description 6
239000000843 powder Substances 0.000 claims description 6
239000007858 starting material Substances 0.000 claims description 6
150000003445 sucroses Chemical class 0.000 claims description 6
229960002663 thioctic acid Drugs 0.000 claims description 6
PIZHURYFCSGTJX-UHFFFAOYSA-L calcium;2-propylpentanoate Chemical compound [Ca+2].CCCC(C([O-])=O)CCC.CCCC(C([O-])=O)CCC PIZHURYFCSGTJX-UHFFFAOYSA-L 0.000 claims description 5
239000011159 matrix material Substances 0.000 claims description 5
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 4
JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 claims description 4
230000003276 anti-hypertensive effect Effects 0.000 claims description 4
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
239000002775 capsule Substances 0.000 claims description 4
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 4
229960003667 flupirtine Drugs 0.000 claims description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
MRWQRJMESRRJJB-UHFFFAOYSA-N pentifylline Chemical compound O=C1N(CCCCCC)C(=O)N(C)C2=C1N(C)C=N2 MRWQRJMESRRJJB-UHFFFAOYSA-N 0.000 claims description 4
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 4
229960004380 tramadol Drugs 0.000 claims description 4
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 4
AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims description 3
AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 3
239000008298 dragée Substances 0.000 claims description 3
235000019136 lipoic acid Nutrition 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
229920006395 saturated elastomer Polymers 0.000 claims description 3
150000004671 saturated fatty acids Chemical class 0.000 claims description 3
235000003441 saturated fatty acids Nutrition 0.000 claims description 3
230000001225 therapeutic effect Effects 0.000 claims description 3
150000004670 unsaturated fatty acids Chemical class 0.000 claims description 3
235000021122 unsaturated fatty acids Nutrition 0.000 claims description 3
MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 3
229960000604 valproic acid Drugs 0.000 claims description 3
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 2
OWYLAEYXIQKAOL-UHFFFAOYSA-N 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone Chemical compound COC1=CC(OC)=CC(OC)=C1C(=O)CCCN1CCCC1 OWYLAEYXIQKAOL-UHFFFAOYSA-N 0.000 claims description 2
MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims description 2
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 2
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 2
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 2
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 2
230000003288 anthiarrhythmic effect Effects 0.000 claims description 2
230000003266 anti-allergic effect Effects 0.000 claims description 2
230000001088 anti-asthma Effects 0.000 claims description 2
230000003178 anti-diabetic effect Effects 0.000 claims description 2
230000003556 anti-epileptic effect Effects 0.000 claims description 2
230000003356 anti-rheumatic effect Effects 0.000 claims description 2
230000003457 anti-vomiting effect Effects 0.000 claims description 2
239000003416 antiarrhythmic agent Substances 0.000 claims description 2
239000000924 antiasthmatic agent Substances 0.000 claims description 2
239000001961 anticonvulsive agent Substances 0.000 claims description 2
239000003472 antidiabetic agent Substances 0.000 claims description 2
239000003435 antirheumatic agent Substances 0.000 claims description 2
229960004574 azelastine Drugs 0.000 claims description 2
BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 2
229960000911 benserazide Drugs 0.000 claims description 2
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 claims description 2
229960000516 bezafibrate Drugs 0.000 claims description 2
229960001415 buflomedil Drugs 0.000 claims description 2
229960001948 caffeine Drugs 0.000 claims description 2
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 2
210000004351 coronary vessel Anatomy 0.000 claims description 2
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 2
WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 claims description 2
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
229960001259 diclofenac Drugs 0.000 claims description 2
MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 claims description 2
229960004993 dimenhydrinate Drugs 0.000 claims description 2
UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 claims description 2
229960001066 disopyramide Drugs 0.000 claims description 2
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 2
229960002297 fenofibrate Drugs 0.000 claims description 2
239000007941 film coated tablet Substances 0.000 claims description 2
229960002490 fosinopril Drugs 0.000 claims description 2
229960004580 glibenclamide Drugs 0.000 claims description 2
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 2
229960004502 levodopa Drugs 0.000 claims description 2
XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 claims description 2
XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 2
229910052808 lithium carbonate Inorganic materials 0.000 claims description 2
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 2
229960002237 metoprolol Drugs 0.000 claims description 2
XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 claims description 2
229960004027 molsidomine Drugs 0.000 claims description 2
229960005181 morphine Drugs 0.000 claims description 2
229940035363 muscle relaxants Drugs 0.000 claims description 2
239000003158 myorelaxant agent Substances 0.000 claims description 2
229960002371 pentifylline Drugs 0.000 claims description 2
229960001476 pentoxifylline Drugs 0.000 claims description 2
229920000728 polyester Polymers 0.000 claims description 2
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 2
229960003908 pseudoephedrine Drugs 0.000 claims description 2
229960001404 quinidine Drugs 0.000 claims description 2
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 2
229960003708 sumatriptan Drugs 0.000 claims description 2
MXFWWQICDIZSOA-UHFFFAOYSA-N talinolol Chemical compound C1=CC(OCC(O)CNC(C)(C)C)=CC=C1NC(=O)NC1CCCCC1 MXFWWQICDIZSOA-UHFFFAOYSA-N 0.000 claims description 2
229960003658 talinolol Drugs 0.000 claims description 2
229960001402 tilidine Drugs 0.000 claims description 2
239000012530 fluid Substances 0.000 claims 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 2
RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 claims 2
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 1
DSFGXPJYDCSWTA-UHFFFAOYSA-N 7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(O)CN(CCO)C DSFGXPJYDCSWTA-UHFFFAOYSA-N 0.000 claims 1
208000019695 Migraine disease Diseases 0.000 claims 1
KBAFPSLPKGSANY-UHFFFAOYSA-N Naftidrofuryl Chemical compound C=1C=CC2=CC=CC=C2C=1CC(C(=O)OCCN(CC)CC)CC1CCCO1 KBAFPSLPKGSANY-UHFFFAOYSA-N 0.000 claims 1
239000000006 Nitroglycerin Substances 0.000 claims 1
UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 claims 1
239000002269 analeptic agent Substances 0.000 claims 1
230000003555 analeptic effect Effects 0.000 claims 1
230000000202 analgesic effect Effects 0.000 claims 1
230000002205 anti-dementic effect Effects 0.000 claims 1
230000001362 anti-vertigo Effects 0.000 claims 1
229960004205 carbidopa Drugs 0.000 claims 1
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 1
229960004166 diltiazem Drugs 0.000 claims 1
239000002934 diuretic Substances 0.000 claims 1
229940030606 diuretics Drugs 0.000 claims 1
RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 claims 1
RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims 1
229960001389 doxazosin Drugs 0.000 claims 1
229960003883 furosemide Drugs 0.000 claims 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
239000001087 glyceryl triacetate Substances 0.000 claims 1
235000013773 glyceryl triacetate Nutrition 0.000 claims 1
229960003711 glyceryl trinitrate Drugs 0.000 claims 1
230000000147 hypnotic effect Effects 0.000 claims 1
229960001132 naftidrofuryl Drugs 0.000 claims 1
229960001085 piretanide Drugs 0.000 claims 1
230000000506 psychotropic effect Effects 0.000 claims 1
239000000932 sedative agent Substances 0.000 claims 1
230000001624 sedative effect Effects 0.000 claims 1
229960000278 theophylline Drugs 0.000 claims 1
229960002622 triacetin Drugs 0.000 claims 1
WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims 1
229960001722 verapamil Drugs 0.000 claims 1
229960002726 vincamine Drugs 0.000 claims 1
229940118318 xanthinol Drugs 0.000 claims 1
238000009472 formulation Methods 0.000 abstract description 23
230000003111 delayed effect Effects 0.000 abstract description 12
230000000694 effects Effects 0.000 abstract description 3
230000004927 fusion Effects 0.000 abstract 2
239000004480 active ingredient Substances 0.000 abstract 1
SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 52
239000000126 substance Substances 0.000 description 40
238000004364 calculation method Methods 0.000 description 20
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
239000000872 buffer Substances 0.000 description 9
239000002245 particle Substances 0.000 description 9
239000007787 solid Substances 0.000 description 8
239000006187 pill Substances 0.000 description 7
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
239000006174 pH buffer Substances 0.000 description 6
230000008901 benefit Effects 0.000 description 5
238000001816 cooling Methods 0.000 description 5
238000009792 diffusion process Methods 0.000 description 5
239000008213 purified water Substances 0.000 description 5
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
239000003925 fat Substances 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000007909 melt granulation Methods 0.000 description 4
239000012071 phase Substances 0.000 description 4
239000000080 wetting agent Substances 0.000 description 4
229920002785 Croscarmellose sodium Polymers 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
229940116224 behenate Drugs 0.000 description 3
UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
229910000389 calcium phosphate Inorganic materials 0.000 description 3
235000011010 calcium phosphates Nutrition 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
239000000470 constituent Substances 0.000 description 3
229960001681 croscarmellose sodium Drugs 0.000 description 3
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
238000009826 distribution Methods 0.000 description 3
238000001035 drying Methods 0.000 description 3
230000003628 erosive effect Effects 0.000 description 3
235000011389 fruit/vegetable juice Nutrition 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
DPYIXBFZUMCMJM-BTJKTKAUSA-N (z)-but-2-enedioic acid;ethyl n-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate Chemical compound OC(=O)\C=C/C(O)=O.N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 DPYIXBFZUMCMJM-BTJKTKAUSA-N 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
239000010408 film Substances 0.000 description 2
238000009501 film coating Methods 0.000 description 2
229960001655 flupirtine maleate Drugs 0.000 description 2
239000000416 hydrocolloid Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000000155 melt Substances 0.000 description 2
230000009965 odorless effect Effects 0.000 description 2
238000007500 overflow downdraw method Methods 0.000 description 2
230000035515 penetration Effects 0.000 description 2
ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
229920000058 polyacrylate Polymers 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000007873 sieving Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
239000001993 wax Substances 0.000 description 2
229940075420 xanthine Drugs 0.000 description 2
IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 1
PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 1
CCTREOMTIFSZAU-OGFXRTJISA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;5-[(3r)-dithiolan-3-yl]pentanoic acid Chemical compound OCC(N)(CO)CO.OC(=O)CCCC[C@@H]1CCSS1 CCTREOMTIFSZAU-OGFXRTJISA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
229920002845 Poly(methacrylic acid) Chemical class 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
208000018300 basal ganglia disease Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
239000007931 coated granule Substances 0.000 description 1
235000020186 condensed milk Nutrition 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
229960004704 dihydroergotamine Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000035876 healing Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
229960004815 meprobamate Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
229960003642 nicergoline Drugs 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000008385 outer phase Substances 0.000 description 1
150000002942 palmitic acid derivatives Chemical class 0.000 description 1
229960000969 phenyl salicylate Drugs 0.000 description 1
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical class [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229960004526 piracetam Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Chemical class 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
229940066675 ricinoleate Drugs 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
238000005245 sintering Methods 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229940084026 sodium valproate Drugs 0.000 description 1
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229940114926 stearate Drugs 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000010409 thin film Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229960003107 tramadol hydrochloride Drugs 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
150000004043 trisaccharides Chemical class 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Oil, Petroleum & Natural Gas (AREA)
Hospice & Palliative Care (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Immunology (AREA)
Anesthesiology (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Emergency Medicine (AREA)
Biophysics (AREA)

BG107064A 2000-03-08 2002-09-05 Фармацевтични форmи BG107064A (bg)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE2000110509 DE10010509A1 (de)	2000-03-08	2000-03-08	Pharmazeutische Formulierungen
US18796200P	2000-03-09	2000-03-09
PCT/EP2001/002500 WO2001066081A2 (fr)	2000-03-08	2001-03-06	Formulations pharmaceutiques

Publications (1)

Publication Number	Publication Date
BG107064A true BG107064A (bg)	2003-04-30

Family

ID=26004678

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107064A BG107064A (bg)	2000-03-08	2002-09-05	Фармацевтични форmи

Country Status (22)

Country	Link
EP (1)	EP1267828B1 (fr)
JP (1)	JP2003528829A (fr)
KR (1)	KR20020083171A (fr)
CN (1)	CN1212831C (fr)
AT (1)	ATE334659T1 (fr)
AU (1)	AU2001250365A1 (fr)
BG (1)	BG107064A (fr)
BR (1)	BR0109036A (fr)
CA (1)	CA2339913C (fr)
CZ (1)	CZ20023009A3 (fr)
DE (1)	DE50110617D1 (fr)
EA (1)	EA200200951A1 (fr)
EE (1)	EE200200504A (fr)
GE (1)	GEP20053455B (fr)
HR (1)	HRP20020804B1 (fr)
HU (1)	HUP0204513A3 (fr)
IS (1)	IS6511A (fr)
NO (1)	NO20024237L (fr)
NZ (1)	NZ521215A (fr)
PL (1)	PL202935B1 (fr)
SK (1)	SK13252002A3 (fr)
WO (1)	WO2001066081A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003074029A1 (fr) *	2002-03-07	2003-09-12	Vectura Limited	Formulations a base de particules multiples a fusion rapide pour administration orale
US20060153915A1 (en) *	2003-01-23	2006-07-13	Amorepacific Corporation	Sustained-release preparations and method for producing the same
DE10341264A1 (de) *	2003-09-04	2005-03-24	Grünenthal GmbH	Schmelzformulierte, multipartikuläre orale Darreichungsform
JP2007533733A (ja) *	2004-04-22	2007-11-22	モルリサーチアプリケーションズリミテッド	食物摂取管理の方法
AU2009270768A1 (en) *	2008-07-18	2010-01-21	Valeant Pharmaceuticals International	Modified release formulation and methods of use
US8715715B2 (en) *	2008-11-03	2014-05-06	Nal Pharmaceuticals Ltd.	Dosage form for insertion into the mouth
DE102009013612A1 (de)	2009-03-17	2010-09-23	Ratiopharm Gmbh	Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
DE102009013611A1 (de)	2009-03-17	2010-09-23	Ratiopharm Gmbh	Festes Retigabin in nicht-kristalliner Form
DE102009013613A1 (de)	2009-03-17	2010-09-23	Ratiopharm Gmbh	Trockenverarbeitung von Retigabin
EP2525660A4 (fr) *	2010-01-20	2013-08-07	Valeant Pharmaceuticals Int	Formulation à libération modifiée et procédés d'utilisation
CA2839350A1 (fr)	2011-07-05	2013-01-10	Contera Pharma Aps	Utilisation d'agonistes de recepteur de serotonine pour le traitement de troubles des mouvements
US9616025B2 (en) *	2013-10-29	2017-04-11	Echo Pharmaceuticals B.V.	Compressed tablet containing Δ9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment
EP3541393A4 (fr) *	2016-11-18	2020-06-17	The University Of Western Australia	Produit de masquage du goût
CN107441055A (zh) *	2017-08-03	2017-12-08	山东则正医药技术有限公司	一种控释药物的制备方法
CN108853044B (zh) *	2018-07-06	2020-11-06	郑州明泽医药科技有限公司	一种硝苯地平缓释片及其制备方法
CN109679147B (zh) *	2018-12-28	2021-05-11	广西科技师范学院	植物微细纤维蔗糖脂肪酸酯富集物及制备方法
GB201904767D0 (en)	2019-04-04	2019-05-22	Orexo Ab	New pharmaceutical compositions
WO2021145625A1 (fr) *	2020-01-13	2021-07-22	한국유나이티드제약 주식회사	Composition pharmaceutique comprenant de l'acide r-thioctique ou son sel pharmaceutiquement acceptable et substance de base d'enrobage entérique
CN111513192A (zh) *	2020-05-19	2020-08-11	北京中联华康科技有限公司	一种酯化半胱胺盐酸盐稳定型粉末及其制备方法与应用
CN114983964B (zh) *	2022-06-24	2024-05-03	广东恒健制药有限公司	一种头孢地尼颗粒剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS63101320A (ja) *	1986-10-17	1988-05-06	Dainippon Pharmaceut Co Ltd	バルプロ酸カルシウム製剤
JPH07267850A (ja) *	1994-03-28	1995-10-17	Eisai Co Ltd	不快味を防止した医薬組成物及びその製造方法
JP4078567B2 (ja) *	1997-04-25	2008-04-23	東和薬品株式会社	徐放性マイクロカプセル及びその製法
JP4299384B2 (ja) *	1997-07-15	2009-07-22	富山化学工業株式会社	溶出遅延防止細粒剤
ME00189B (me) *	1998-03-26	2011-02-10	Astellas Pharma Inc	Preparati sa neprekidnim oslobađanjem
DE19840152A1 (de) *	1998-09-03	2000-03-09	Dresden Arzneimittel	Calciumvalproat enthaltende pharmazeutische Zusammensetzungen mit retardierter Wirkstoff-Freisetzung, Verfahren zu deren Herstellung und deren Verwendung
DE19916383A1 (de) *	1999-03-31	2000-10-05	Schering Ag	Pharmazeutische Zusammensetzung mit einem Extrusionsstoff

2001
- 2001-03-06 CN CNB018061893A patent/CN1212831C/zh not_active Expired - Fee Related
- 2001-03-06 HU HU0204513A patent/HUP0204513A3/hu unknown
- 2001-03-06 PL PL362547A patent/PL202935B1/pl not_active IP Right Cessation
- 2001-03-06 WO PCT/EP2001/002500 patent/WO2001066081A2/fr not_active Ceased
- 2001-03-06 EP EP01923641A patent/EP1267828B1/fr not_active Revoked
- 2001-03-06 NZ NZ521215A patent/NZ521215A/en unknown
- 2001-03-06 JP JP2001564734A patent/JP2003528829A/ja active Pending
- 2001-03-06 AT AT01923641T patent/ATE334659T1/de not_active IP Right Cessation
- 2001-03-06 DE DE50110617T patent/DE50110617D1/de not_active Revoked
- 2001-03-06 EE EEP200200504A patent/EE200200504A/xx unknown
- 2001-03-06 KR KR1020027011672A patent/KR20020083171A/ko not_active Ceased
- 2001-03-06 GE GE4946A patent/GEP20053455B/en unknown
- 2001-03-06 CZ CZ20023009A patent/CZ20023009A3/cs unknown
- 2001-03-06 SK SK1325-2002A patent/SK13252002A3/sk not_active Application Discontinuation
- 2001-03-06 AU AU2001250365A patent/AU2001250365A1/en not_active Abandoned
- 2001-03-06 BR BR0109036-4A patent/BR0109036A/pt not_active Application Discontinuation
- 2001-03-06 EA EA200200951A patent/EA200200951A1/ru unknown
- 2001-03-06 HR HR20020804A patent/HRP20020804B1/xx not_active IP Right Cessation
- 2001-03-07 CA CA002339913A patent/CA2339913C/fr not_active Expired - Fee Related
2002
- 2002-08-20 IS IS6511A patent/IS6511A/is unknown
- 2002-09-05 BG BG107064A patent/BG107064A/bg unknown
- 2002-09-05 NO NO20024237A patent/NO20024237L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20024237D0 (no)	2002-09-05
EE200200504A (et)	2004-02-16
GEP20053455B (en)	2005-02-25
ATE334659T1 (de)	2006-08-15
DE50110617D1 (de)	2006-09-14
EP1267828B1 (fr)	2006-08-02
PL362547A1 (en)	2004-11-02
HRP20020804A2 (en)	2004-12-31
CN1212831C (zh)	2005-08-03
NZ521215A (en)	2005-04-29
HUP0204513A2 (en)	2003-05-28
HRP20020804B1 (en)	2008-06-30
WO2001066081A3 (fr)	2002-03-14
WO2001066081A2 (fr)	2001-09-13
JP2003528829A (ja)	2003-09-30
HUP0204513A3 (en)	2004-06-28
BR0109036A (pt)	2003-03-18
PL202935B1 (pl)	2009-08-31
EP1267828A2 (fr)	2003-01-02
KR20020083171A (ko)	2002-11-01
NO20024237L (no)	2002-09-05
IS6511A (is)	2002-08-20
CZ20023009A3 (cs)	2003-06-18
CA2339913A1 (fr)	2001-09-08
AU2001250365A1 (en)	2001-09-17
HK1054697A1 (en)	2003-12-12
CN1418091A (zh)	2003-05-14
CA2339913C (fr)	2009-02-24
SK13252002A3 (sk)	2003-07-01
EA200200951A1 (ru)	2003-02-27

Publication	Publication Date	Title
US20060029670A1 (en)	2006-02-09	Pharmaceutical Formulations and Method for Making
BG107064A (bg)	2003-04-30	Фармацевтични форmи
US5807583A (en)	1998-09-15	Process for the preparation of sustained release pellets
JP2003528829A6 (ja)	2004-07-08	薬剤学的製剤
TW200529803A (en)	2005-09-16	Extrusion process for forming chemically stable drug multiparticulates
PT1741426E (pt)	2008-09-01	Formulações de hidromorfona administráveis por via oral e obtidas por extrusão de uma massa fundida
US20030203026A1 (en)	2003-10-30	Therapeutic agents
JPH04217913A (ja)	1992-08-07	被覆製剤およびその製造法
WO2005053651A1 (fr)	2005-06-16	Compositions multiparticulaires a stabilite amelioree
US7951403B2 (en)	2011-05-31	Method of making pharmaceutical multiparticulates
JP2004532270A (ja)	2004-10-21	顆粒組成物および顆粒外組成物を含むｎｓａｉｄ製剤
AU2002302786A1 (en)	2003-05-08	Nsaid formulation comprising a granular composition and an extra-granular composition
EP2376061A1 (fr)	2011-10-19	Compositions aqueuses coacervées comprenant des agents biologiquement actifs faiblement solubles dans l'eau
ZA200207050B (en)	2002-11-20	Pharmaceutical preparations.
RS59351B1 (sr)	2019-10-31	Čvrste oralne formulacije koje sadrže čvrste rastopljene disperzije organskih kiselina u ksilitolu
JPWO2000004896A1 (ja)	2001-09-25	難溶性ＮＳＡＩＤｓ含有固形製剤
MXPA06006032A (es)	2006-10-17	Metodo para preparar multiparticulas farmaceuticas
EA006846B1 (ru)	2006-04-28	Болеутоляющая композиция для перорального применения с регулируемым высвобождением опиоида
MXPA06006034A (en)	2006-10-17	Multiparticulate compositions with improved stability